ARBs, ACEIs useful for treating COVID-19 patients with pre-existing hypertension
Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) show superiority over other blood pressure (BP)-lowering medications in terms of reducing high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels in COVID-19 patients with pre-existing hypertension, as shown in a recent study.
ARBs, ACEIs useful for treating COVID-19 patients with pre-existing hypertension
23 May 2020
